Under one in 10 individuals eligible to benefit from GLP-1 drugs like Wegovy are able to get them, states the global health agency as it releases its initial guidance on the therapies.
With in excess of 1,000,000,000 people worldwide currently classified as obese, it is urging more widespread and fairer availability to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"Our new guidance recognises that obesity is a lifelong illness that can be addressed with holistic and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are significant hurdles to broad access to the jabs that can assist patients in reducing significant body mass, explains the agency.
GLP-1 Therapy Shortage
Even in the present most favorable case, the production of GLP-1 therapies might only reach about 100 million people – fewer than 10% of the global need, as stated by the health organization.
The recommendation encourages governments and firms to expand access, by strategies such as licensing agreements.
The intellectual property rights on the active ingredient – the primary ingredient of a leading brand – is due to expire in several countries in 2026.
The Way Weight-Loss Injections Work
GLP-1 drugs imitate a natural hormone to slow digestion, reduce hunger and boost satiety so individuals eat less.
People usually see weight reduction within a few weeks of beginning the once-weekly jabs.
Research indicates people may see weight return a year later of discontinuing the medication, because their typical appetite resume.
To be carrying excess weight elevates your chance for experiencing diseases, including diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight concerns individuals in all nations and was responsible for over three and a half million deaths worldwide in 2024, per the WHO.
